CA3167223A1 - Interventions therapeutiques recombinantes contre le cancer - Google Patents

Interventions therapeutiques recombinantes contre le cancer Download PDF

Info

Publication number
CA3167223A1
CA3167223A1 CA3167223A CA3167223A CA3167223A1 CA 3167223 A1 CA3167223 A1 CA 3167223A1 CA 3167223 A CA3167223 A CA 3167223A CA 3167223 A CA3167223 A CA 3167223A CA 3167223 A1 CA3167223 A1 CA 3167223A1
Authority
CA
Canada
Prior art keywords
bcg
disa
cells
protein
tumor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3167223A
Other languages
English (en)
Inventor
William R. Bishai
Trinity J. BIVALACQUA
Alok Singh
Monali PRAHARAJ
Takahiro Yoshida
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Johns Hopkins University
Original Assignee
Individual
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Individual filed Critical Individual
Publication of CA3167223A1 publication Critical patent/CA3167223A1/fr
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/74—Vectors or expression systems specially adapted for prokaryotic hosts other than E. coli, e.g. Lactobacillus, Micromonospora
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/66—Microorganisms or materials therefrom
    • A61K35/74—Bacteria
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/04—Mycobacterium, e.g. Mycobacterium tuberculosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/70—Vectors or expression systems specially adapted for E. coli
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
    • A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
    • A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/54—Medicinal preparations containing antigens or antibodies characterised by the route of administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/555—Medicinal preparations containing antigens or antibodies characterised by a specific combination antigen/adjuvant
    • A61K2039/55588—Adjuvants of undefined constitution
    • A61K2039/55594—Adjuvants of undefined constitution from bacteria

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Microbiology (AREA)
  • Organic Chemistry (AREA)
  • Zoology (AREA)
  • General Engineering & Computer Science (AREA)
  • Wood Science & Technology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Biotechnology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Biomedical Technology (AREA)
  • Mycology (AREA)
  • Molecular Biology (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Plant Pathology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biophysics (AREA)
  • Physics & Mathematics (AREA)
  • Biochemistry (AREA)
  • Communicable Diseases (AREA)
  • Pulmonology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

L'invention concerne des procédés pour supprimer l'expression de cellules myéloïdes suppressives (MDSC), de macrophages M2 et de lymphocytes Treg dans une tumeur et induire l'expression de macrophages, de cellules dendritiques (DC) et de lymphocytes T effecteurs dans une tumeur chez un sujet. Une composition pharmaceutique comprenant une souche de mycobactéries comprenant un vecteur d'expression de la présente invention est administrée à un sujet.
CA3167223A 2020-02-13 2021-02-12 Interventions therapeutiques recombinantes contre le cancer Pending CA3167223A1 (fr)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202016790161A 2020-02-13 2020-02-13
US16/790,161 2020-02-13
PCT/US2021/018007 WO2021163602A1 (fr) 2020-02-13 2021-02-12 Interventions thérapeutiques recombinantes contre le cancer

Publications (1)

Publication Number Publication Date
CA3167223A1 true CA3167223A1 (fr) 2021-08-19

Family

ID=77292873

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3167223A Pending CA3167223A1 (fr) 2020-02-13 2021-02-12 Interventions therapeutiques recombinantes contre le cancer

Country Status (6)

Country Link
EP (1) EP4103208A4 (fr)
JP (1) JP2023514553A (fr)
CN (1) CN115443143A (fr)
AU (1) AU2021220986A1 (fr)
CA (1) CA3167223A1 (fr)
WO (1) WO2021163602A1 (fr)

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2620159A1 (fr) * 2012-01-24 2013-07-31 Institut Pasteur Traitement du cancer amélioré par immunothérapie par BCG ou des mycobactéries non pathogènes apparentées du point de vue des antigènes
WO2018112360A1 (fr) * 2016-12-16 2018-06-21 Evelo Biosciences, Inc. Polythérapies pour le traitement du cancer
CN110913875A (zh) * 2017-01-06 2020-03-24 同生运营公司 程序化以在肿瘤细胞中产生免疫调节子和抗癌治疗剂的微生物
SG11201911031TA (en) * 2017-07-12 2020-01-30 Synlogic Operating Co Inc Microorganisms programmed to produce immune modulators and anti-cancer therapeutics in tumor cells
AU2019257190A1 (en) * 2018-04-17 2020-11-19 The Johns Hopkins University Recombinant therapeutic interventions for cancer
US20210299187A1 (en) * 2018-06-25 2021-09-30 Immodulon Therapeutics Limited Cancer therapy

Also Published As

Publication number Publication date
EP4103208A1 (fr) 2022-12-21
CN115443143A (zh) 2022-12-06
WO2021163602A1 (fr) 2021-08-19
EP4103208A4 (fr) 2024-05-08
JP2023514553A (ja) 2023-04-06
AU2021220986A1 (en) 2022-09-01

Similar Documents

Publication Publication Date Title
US20210024940A1 (en) Recombinant therapeutic interventions for cancer
WO2019157098A1 (fr) Compositions comprenant une souche de listeria recombinante et un anticorps anti-ccr8 et méthodes d'utilisation
JP2020531046A (ja) 遺伝子操作された免疫刺激性細菌菌株およびその使用
Alpdundar Bulut et al. Human gut commensal membrane vesicles modulate inflammation by generating M2-like macrophages and myeloid-derived suppressor cells
US10130663B2 (en) Bacteria over-expressing c-di-AMP and therapeutic methods
Jeyanathan et al. Pulmonary M. tuberculosis infection delays Th1 immunity via immunoadaptor DAP12-regulated IRAK-M and IL-10 expression in antigen-presenting cells
CN112533624A (zh) 用于治疗癌症的pla2-g1b辅因子抑制剂
Begnini et al. Recombinant Mycobacterium bovis BCG for immunotherapy in nonmuscle invasive bladder cancer
IL277421A (en) compounds
Chan et al. Role of D-alanylation of Streptococcus gordonii lipoteichoic acid in innate and adaptive immunity
US10238738B2 (en) Methods of modulating immune system responses
WO2018085275A1 (fr) Ciblage de lats1/2 et de la voie de signalisation intracellulaire hippo pour immunothérapie anticancéreuse
JP6786074B2 (ja) エキソソーム標的ｄｎａワクチン
WO2018183930A1 (fr) Procédés d'isolement, d'expansion et d'administration de lymphocytes t cd8+ spécifiques du cancer
Mackie et al. Bacterial cancer therapy in autochthonous colorectal cancer affects tumor growth and metabolic landscape
US20230092817A1 (en) Recombinant therapeutic interventions for cancer
CA3167223A1 (fr) Interventions therapeutiques recombinantes contre le cancer
Kim et al. OspF directly attenuates the activity of extracellular signal-regulated kinase during invasion by Shigella flexneri in human dendritic cells
JP2023529957A (ja) がん治療
JP5994127B2 (ja) 新規な組換えｂｃｇワクチン
Um et al. Improved bladder cancer antitumor efficacy with a recombinant BCG that releases a STING agonist
KR20200058320A (ko) 항균 펩타이드 회피 유전자를 포함하는 재조합 바실러스 칼메트-게렝균의 방광암 항암 치료용 약학적 조성물
Shaku et al. A modified BCG with depletion of enzymes associated with peptidoglycan amidation induces enhanced protection against tuberculosis in mice
US20230002502A1 (en) Methods and products for reducing side effects associated with use of immune agonist antibodies
US20240100133A1 (en) Enzymatically inactive granzyme a and uses therefore